Loading...

Precision BioSciences

DB:PBS
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBS
DB
$628M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
  • Precision BioSciences has significant price volatility in the past 3 months.
PBS Share Price and Events
7 Day Returns
-0.4%
DB:PBS
0.3%
DE Biotechs
-0.2%
DE Market
1 Year Returns
-
DB:PBS
-8.3%
DE Biotechs
-10.4%
DE Market
PBS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Precision BioSciences (PBS) -0.4% 1.8% - - - -
DE Biotechs 0.3% 1.9% -1% -8.3% 58.9% 13%
DE Market -0.2% -2.1% 4.2% -10.4% 11.1% 10.6%
1 Year Return vs Industry and Market
  • No trading data on PBS.
  • No trading data on PBS.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

PBS Value

 Is Precision BioSciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Precision BioSciences. This is due to cash flow or dividend data being unavailable. The share price is €11.506.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Precision BioSciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Precision BioSciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PBS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-4.34
NasdaqGS:DTIL Share Price ** NasdaqGS (2019-05-17) in USD $12.46
Europe Biotechs Industry PE Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 22.59x
Germany Market PE Ratio Median Figure of 426 Publicly-Listed Companies 20.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Precision BioSciences.

DB:PBS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:DTIL Share Price ÷ EPS (both in USD)

= 12.46 ÷ -4.34

-2.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Precision BioSciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Precision BioSciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Precision BioSciences's expected growth come at a high price?
Raw Data
DB:PBS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
19.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Precision BioSciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Precision BioSciences's assets?
Raw Data
DB:PBS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.67
NasdaqGS:DTIL Share Price * NasdaqGS (2019-05-17) in USD $12.46
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.35x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.79x
DB:PBS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:DTIL Share Price ÷ Book Value per Share (both in USD)

= 12.46 ÷ 0.67

18.48x

* Primary Listing of Precision BioSciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Precision BioSciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Precision BioSciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Precision BioSciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PBS Future Performance

 How is Precision BioSciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Precision BioSciences expected to grow at an attractive rate?
  • Precision BioSciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Precision BioSciences's earnings growth is expected to exceed the Germany market average.
  • Precision BioSciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PBS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PBS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 19.3%
DB:PBS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 47.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 52.3%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 32.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PBS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PBS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 277 88 69 1
2022-12-31 46 -95 -119 1
2021-12-31 57 -58 -100 3
2020-12-31 31 -96 -134 2
2019-12-31 34 -53 -94 3
DB:PBS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 15 -57 -69
2018-12-31 11 -52 -46
2018-09-30 7 -46 -38
2017-12-31 6 -24 -21
2016-12-31 7 92 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Precision BioSciences's earnings are expected to grow by 19.3% yearly, however this is not considered high growth (20% yearly).
  • Precision BioSciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PBS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Precision BioSciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PBS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.90 0.90 0.90 1.00
2022-12-31 -1.76 -1.76 -1.76 1.00
2021-12-31 -1.40 -0.53 -2.28 2.00
2020-12-31 -2.24 -2.20 -2.28 2.00
2019-12-31 -2.38 -1.76 -3.01 2.00
DB:PBS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -4.34
2018-12-31 -2.92
2018-09-30 -2.41
2017-12-31 -1.33
2016-12-31 -0.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Precision BioSciences will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Precision BioSciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Precision BioSciences has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PBS Past Performance

  How has Precision BioSciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Precision BioSciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Precision BioSciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Precision BioSciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Precision BioSciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Precision BioSciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Precision BioSciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PBS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 14.82 -68.81 17.78 55.21
2018-12-31 10.88 -46.04 15.10 43.69
2018-09-30 7.47 -37.98 12.21 34.56
2017-12-31 6.48 -21.10 8.85 19.49
2016-12-31 7.02 -8.25 6.62 9.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Precision BioSciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Precision BioSciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Precision BioSciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Precision BioSciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Precision BioSciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PBS Health

 How is Precision BioSciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Precision BioSciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Precision BioSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Precision BioSciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Precision BioSciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Precision BioSciences Company Filings, last reported 1 month ago.

DB:PBS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 10.83 52.44 116.50
2018-12-31 39.96 0.00 103.19
2018-09-30 53.59 0.00 127.57
2017-12-31 -26.37 0.00 62.80
2016-12-31 -4.75 0.00 93.42
  • Precision BioSciences's level of debt (484.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if Precision BioSciences's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Precision BioSciences has sufficient cash runway for 1.5 years based on current free cash flow.
  • Precision BioSciences has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 113.5% each year.
X
Financial health checks
We assess Precision BioSciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Precision BioSciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PBS Dividends

 What is Precision BioSciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Precision BioSciences dividends. Estimated to be 0% next year.
If you bought €2,000 of Precision BioSciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Precision BioSciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Precision BioSciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PBS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PBS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Precision BioSciences has not reported any payouts.
  • Unable to verify if Precision BioSciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Precision BioSciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Precision BioSciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Precision BioSciences's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Precision BioSciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Precision BioSciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Precision BioSciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PBS Management

 What is the CEO of Precision BioSciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Matt Kane
AGE 41
TENURE AS CEO 13.3 years
CEO Bio

Mr. Matthew R. Kane, also known as Matt, co-founded Precision BioSciences, Inc. and has been its President, Chief Executive Officer and director since inception in 2006. Mr. Kane has a wealth of life science business development and technical experience. He also serves as a Venture Partner at NextGen Venture Partners. Previously, Mr. Kane was an integral part of Suros Surgical Systems, a venture-backed, breast cancer-focused firm. Mr. Kane was named one of the 40 Under 40 by the Triangle Business Journal and has worked with two seed stage venture capital firms. He received his M.S. in Bio Engineering from the Rose-Hulman Institute of Technology and an MBA from Duke University.

CEO Compensation
  • Insufficient data for Matt to compare compensation growth.
  • Insufficient data for Matt to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Precision BioSciences management team in years:

1.8
Average Tenure
43.5
Average Age
  • The average tenure for the Precision BioSciences management team is less than 2 years, this suggests a new team.
Management Team

Matt Kane

TITLE
Co-Founder
AGE
41
TENURE
13.3 yrs

Derek Jantz

TITLE
Co-founder
AGE
42

Jeff Smith

TITLE
Co-Founder & CTO

Abid Ansari

TITLE
Chief Financial Officer
AGE
40
TENURE
0.3 yrs

Molly Lukes

TITLE
Director of Human Resources

Michael Nicholson

TITLE
Chief People Officer

Bruce McCreedy

TITLE
Senior Vice President of Cell Therapy
AGE
59
TENURE
3.7 yrs

David Thomson

TITLE
Chief Development Officer
AGE
57
TENURE
1.8 yrs

Chris Heery

TITLE
Chief Medical Officer

Fayaz Khazi

TITLE
Chief Executive Officer of Elo Life Systems
AGE
45
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Precision BioSciences board of directors in years:

13.3
Average Tenure
57
Average Age
  • The average tenure for the Precision BioSciences board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Derek Jantz

TITLE
Co-founder
AGE
42
TENURE
13.3 yrs

Ray Schinazi

TITLE
Member of Scientific Advisory Board & Director
AGE
68

Matt Kane

TITLE
Co-Founder
AGE
41
TENURE
13.3 yrs

Shalini Sharp

TITLE
Director
AGE
43
TENURE
0.4 yrs

Paul Billings

TITLE
Member of Advisory Board
AGE
66

Ralph Dewey

TITLE
Member of Advisory Board

June Medford

TITLE
Member of Advisory Board

Jon Stonehouse

TITLE
Member of Advisory Board
AGE
57

M. Zirakparvar

TITLE
Member of Advisory Board
AGE
68

Scott Uknes

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Apr 19 Buy ArrowMark Colorado Holdings, LLC Company 03. Apr 19 03. Apr 19 6,487 €13.73 €89,036
03. Apr 19 Buy Impresa Management LLC Company 01. Apr 19 01. Apr 19 50,000 €14.27 €713,280
01. Apr 19 Buy venBio LLC Company 01. Apr 19 01. Apr 19 50,000 €14.27 €713,280
X
Management checks
We assess Precision BioSciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Precision BioSciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PBS News

Simply Wall St News

PBS Company Info

Description

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Details
Name: Precision BioSciences, Inc.
PBS
Exchange: DB
Founded: 2006
$562,246,132
50,361,705
Website: http://www.precisionbiosciences.com
Address: Precision BioSciences, Inc.
Dibrell Building,
Suite A-100,
Durham,
North Carolina, 27701,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS DTIL Common Stock Nasdaq Global Select US USD 28. Mar 2019
DB PBS Common Stock Deutsche Boerse AG DE EUR 28. Mar 2019
Number of employees
Current staff
Staff numbers
146
Precision BioSciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/18 23:35
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/01
Last earnings filing: 2019/04/29
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.